In my May 2 2024 post, I disclosed that Paycom's (PAYC) attractive valuation prompted me to acquire additional shares @ ~$163 thus bringing my exposure to 700 shares in a 'Core' account within the FFJ Portfolio. At the time of that post, the most currently available financial information was for Q1 2024 and the Q2 [...]
I have Thermo Fisher Scientific (TMO) exposure but it is on my 'Watch' list since I think there will be an opportunity to acquire shares at a more favorable valuation within the next 12 months. I last reviewed TMO in this July 26, 2024 post at which time I concluded that shares were overvalued. Now [...]
In my August 2, 2024 Mastercard (MA) post, I disclosed the purchase of an additional 300 shares @ ~$432.05 in one of the 'Side' accounts within the FFJ Portfolio. On October 31, MA released its Q3 and YTD2024 results and Q4 outlook. I, therefore, revisit MA to determine if I should increase my exposure. Business [...]
We see from this FFJ Portfolio - October 2024 report that I am not aggressively deploying liquidity I have sitting on the sidelines. Purchases I made the following small purchases during the month: HEICO (Class A) (HEI-a) 100 shares @ ~$195.58 on October 28 in a 'Core' account. This brings my HEI-a exposure to 600 [...]
In my Walmart (WMT) guest post at Dividend Power, I touch upon why I do not think it is a safe investment decision at the current valuation. There is nothing fundamentally wrong about the company. The issue I have is that we are experiencing a period of irrational exuberance. Some investors are paying little regard [...]